


**PRECISION RESEARCH INSTITUTE**  
**CURRICULUM VITAE**

Signature: 

Date: 22 Jun 2022

<b>NAME:</b>	Katherine M. Shaffer, MD	<b>DATE</b>	
<b>TITLE:</b>	Investigator/Laboratory Director	<b>UPDATED:</b>	June 2022

**RESEARCH SITE ADDRESS & PHONE:**

<b>Main Office:</b> Precision Research Institute 2732 Navajo Rd, Suite 202 El Cajon, CA. 92020.  <b>Contact Info:</b> Office: (619)501-0371 Fax: (619)501-0390 Email: DrKShaffer@prisandiego.com	<b>Site Number 2:</b> Precision Research Institute 292 Euclid Avenue, Suite 115 San Diego, CA 92114  <b>Contact Info:</b> Office: (619)501-0371 Fax: (619)501-0390 Email: DrKShaffer@prisandiego.com	<b>Site Number 3:</b> Precision Research Institute 296 H Street, Suite 302 Chula Vista, CA 91910  <b>Contact Info:</b> Office: (619)501-0371 Fax: (619)501-0390 Email: DrKShaffer@prisandiego.com
--	--	---

**EDUCATION/TRAINING:**

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Collaborative Institutional Training Initiative (CITI)	Certificate	2020	Good Clinical Practices
University of California San Diego		2015-2018	Fellowship
Emory University Hospital		2012-2015	Internal Medicine
Georgetown University School of Medicine	M.D.	2008-2012	Medical School
University of Virginia	B. S	2003-2007	Chemistry

**BOARD CERTIFIED:**

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
Board Certified	2015	Internal Medicine
Board Eligible	2018	Gastroenterology

## POSITIONS AND EMPLOYMENT:

2022-Present	Laboratory Director, Precision Research Institute-Navajo, El Cajon, CA
2022-Present	Principal Investigator, Precision Research Institute, San Diego, CA
2021-Present	Sub-Investigator, Precision Research Institute, San Diego, CA
2018-Present	Endoscopist, Euclid Endoscopy Center, San Diego, CA
2018-Present	Endoscopist, Euclid Endoscopy Center, Chula Vista, CA
2018-Present	Endoscopist, Euclid Endoscopy Center, El Cajon, CA
2018-Present	Investigator-Precision Research Institute, LLC, San Diego, CA
2018-Present	Gastroenterologist, Digestive Disease Associates, San Diego, CA

## RESEARCH EXPERIENCE:

### Principal Investigator

Cristcot HCA, LLC: A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel XXXXXXXXXX Suppository Formulation Administered with the XXXXXXXXXX Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum

Janssen Research & Development: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of XXXXXXX in Participants with Moderately to Severely Active Crohn's Disease

### Sub-Investigator

Freenome: PREvention Employing a XXXXXXXXXXXX Test for ColoRectal Cancer

Pfizer: A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy And Safety Of XXXXXXXXXXXXXXXX Alone And When Coadministered With XXXXXXXXXXXXXXXX In Adult Participants With Biopsy-Confirmed Nonalcoholic Steatohepatitis And Fibrosis Stage 2 Or 3

Hanmi: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of XXXXXXXXXX Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Takeda: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXXXXXX for the Prevention of Gluten-Specific T Cell Activation in Subjects with Celiac Disease on a Gluten-Free Diet

Guardant: Evaluation of the XXXXXXXX Test in an Average Patient Screening Episode (ECLIPSE)

Phathom: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral XXXXXXXXXX or Double-Blind Triple Therapy with Oral XXXXXXXXXX Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection

Phathom: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of XXXXXXXXXX Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of XXXXXXXXXX Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis

Pfizer: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study To Evaluate Safety, Tolerability And Pharmacodynamics Of XXXXXXXX Administered Daily For 16 Weeks In Adults With Non-Alcoholic Fatty Liver Disease And Type 2 Diabetes Mellitus On Metformin

Nivagen: Randomized Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Pilot Study Of The Safety And Efficacy Of XXXXXXXXXXXXXXXX, 25 MG Compared To Placebo Suppositories In The Treatment Of Symptomatic Internal Hemorrhoids

Braintree: A Safety and Efficacy Comparison of XXXXXXXX Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy

Freenome: PREvention Employing a XXXXXXXXXX Test for ColoRectal Cancer

Ironwood: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral XXXXXXX Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors

Janssen: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With XXXXXXXXXX and XXXXXXXXXX in Participants With Moderately to Severely Active Ulcerative Colitis

Enanta: A Phase 2 dose ranging, Randomized, Double-Blind, and Placebo-Controlled study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of XXXX in Subjects with Non-Alcoholic Steatohepatitis (NASH)

Eli Lilly: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of XXXXXXXXXX in Patients with Moderately to Severely Active Crohn's Disease

ObsEva: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Efficacy and Safety of XXXXXXXXXX in Subjects with Moderate to Severe Endometriosis-Associated Pain.

Arena: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of XXXXXXXX in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain